Loading discussion content. Please wait...
Brain Cap 40 Hz Gamma Induction, Boston MA
Device: Transcranial Alternating Current Stimulation (tACS)
This is the Cell Phone Wave Cap that Steve3D posted about.
A very similar study is being run in Aurora Colorado
University of Colorado AMCAurora, Colorado, United States
Study Type :
Interventional (Clinical Trial)
Estimated Enrollment :
Triple (Participant, Care Provider, Outcomes Assessor)
Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Actual Study Start Date :
March 7, 2018
Estimated Primary Completion Date :
Estimated Study Completion Date :
If you still think stimulating the brain via TACS (Transcranial Alternating Current Stimulation) is a sham, don't look at this page of 29 studies on it.
Wait, wait, 2 of these are about how coffee stimulates the brain, so correction, 27 current studies of TACS, which is non-invasive, so much so that sometimes ITS A HAT you wear for 2 hours a day.
Not yet recruiting
Small aggregates (oligomers) of the toxic proteins amyloid-β (Aβ) and phospho-tau (p-tau) are essential contributors to Alzheimer’s disease (AD). In mouse models for AD or human AD brain extracts, Transcranial Electromagnetic Treatment (TEMT) disaggregates both Aβ and p-tau oligomers, and induces brain mitochondrial enhancement. These apparent “disease-modifying” actions of TEMT both prevent and reverse memory impairment in AD transgenic mice.
To evaluate the safety and initial clinical efficacy of TEMT against AD, a comprehensive open-label clinical trial was performed.
Eight mild/moderate AD patients were treated with TEMT in-home by their caregivers for 2 months utilizing a unique head device. TEMT was given for two 1-hour periods each day, with subjects primarily evaluated at baseline, end-of-treatment, and 2 weeks following treatment completion.
No deleterious behavioral effects, discomfort, or physiologic changes resulted from 2 months of TEMT, as well as no evidence of tumor or microhemorrhage induction.
TEMT induced clinically important and statistically significant improvements in ADAS-cog, as well as in the Rey AVLT.
TEMT also produced increases in cerebrospinal fluid (CSF) levels of soluble Aβ1-40 and Aβ1-42, cognition-related changes in CSF oligomeric Aβ, a decreased CSF p-tau/Aβ1-42 ratio, and reduced levels of oligomeric Aβ in plasma.
Pre- versus post-treatment FDG-PET brain scans revealed stable cerebral glucose utilization, with several subjects exhibiting enhanced glucose utilization.
Evaluation of diffusion tensor imaging (fractional anisotropy) scans in individual subjects provided support for TEMT-induced increases in functional connectivity within the cognitively-important cingulate cortex/cingulum.
TEMT administration to AD subjects appears to be safe, while providing cognitive enhancement, changes to CSF/blood AD markers, and evidence of stable/enhanced brain connectivity.